These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19751398)

  • 1. A mouse model for studying dengue virus pathogenesis and immune response.
    Williams KL; Zompi S; Beatty PR; Harris E
    Ann N Y Acad Sci; 2009 Sep; 1171 Suppl 1():E12-23. PubMed ID: 19751398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody Epitopes Identified in Critical Regions of Dengue Virus Nonstructural 1 Protein in Mouse Vaccination and Natural Human Infections.
    Hertz T; Beatty PR; MacMillen Z; Killingbeck SS; Wang C; Harris E
    J Immunol; 2017 May; 198(10):4025-4035. PubMed ID: 28381638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dengue Virus Infection with Highly Neutralizing Levels of Cross-Reactive Antibodies Causes Acute Lethal Small Intestinal Pathology without a High Level of Viremia in Mice.
    Watanabe S; Chan KW; Wang J; Rivino L; Lok SM; Vasudevan SG
    J Virol; 2015 Jun; 89(11):5847-61. PubMed ID: 25787279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maternally Acquired Zika Antibodies Enhance Dengue Disease Severity in Mice.
    Fowler AM; Tang WW; Young MP; Mamidi A; Viramontes KM; McCauley MD; Carlin AF; Schooley RT; Swanstrom J; Baric RS; Govero J; Diamond MS; Shresta S
    Cell Host Microbe; 2018 Nov; 24(5):743-750.e5. PubMed ID: 30439343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models.
    Shukla R; Beesetti H; Brown JA; Ahuja R; Ramasamy V; Shanmugam RK; Poddar A; Batra G; Krammer F; Lim JK; Kale S; Lal AA; Swaminathan S; Khanna N
    EBioMedicine; 2020 Oct; 60():102991. PubMed ID: 32949997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.
    Ramasamy V; Arora U; Shukla R; Poddar A; Shanmugam RK; White LJ; Mattocks MM; Raut R; Perween A; Tyagi P; de Silva AM; Bhaumik SK; Kaja MK; Villinger F; Ahmed R; Johnston RE; Swaminathan S; Khanna N
    PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006191. PubMed ID: 29309412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A lethal murine infection model for dengue virus 3 in AG129 mice deficient in type I and II interferon receptors leads to systemic disease.
    Sarathy VV; White M; Li L; Gorder SR; Pyles RB; Campbell GA; Milligan GN; Bourne N; Barrett AD
    J Virol; 2015 Jan; 89(2):1254-66. PubMed ID: 25392217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection.
    Pinto AK; Brien JD; Lam CY; Johnson S; Chiang C; Hiscott J; Sarathy VV; Barrett AD; Shresta S; Diamond MS
    mBio; 2015 Sep; 6(5):e01316-15. PubMed ID: 26374123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-Reactive T Cell Immunity to Dengue and Zika Viruses: New Insights Into Vaccine Development.
    Elong Ngono A; Shresta S
    Front Immunol; 2019; 10():1316. PubMed ID: 31244855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
    Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein.
    Budigi Y; Ong EZ; Robinson LN; Ong LC; Rowley KJ; Winnett A; Tan HC; Hobbie S; Shriver Z; Babcock GJ; Alonso S; Ooi EE
    PLoS Negl Trop Dis; 2018 Feb; 12(2):e0006209. PubMed ID: 29425203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective Capacity of the Human Anamnestic Antibody Response during Acute Dengue Virus Infection.
    Xu M; Züst R; Toh YX; Pfaff JM; Kahle KM; Davidson E; Doranz BJ; Velumani S; Tukijan F; Wang CI; Fink K
    J Virol; 2016 Dec; 90(24):11122-11131. PubMed ID: 27707930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Epitope-Substituted DNA Vaccine Improves Safety and Immunogenicity against Dengue Virus Type 2.
    Tang CT; Li PC; Liu IJ; Liao MY; Chiu CY; Chao DY; Wu HC
    PLoS Negl Trop Dis; 2015; 9(7):e0003903. PubMed ID: 26135599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of Monoclonal Antibodies against Dengue Virus Type 4 and Identification of Enhancing Epitopes on Envelope Protein.
    Tang CT; Liao MY; Chiu CY; Shen WF; Chiu CY; Cheng PC; Chang GJ; Wu HC
    PLoS One; 2015; 10(8):e0136328. PubMed ID: 26309127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
    Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
    J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approaches to Interrogating the Human Memory B-Cell and Memory-Derived Antibody Repertoire Following Dengue Virus Infection.
    Lyski ZL; Messer WB
    Front Immunol; 2019; 10():1276. PubMed ID: 31244836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct and indirect interactions in the recognition between a cross-neutralizing antibody and the four serotypes of dengue virus.
    Lisova O; Belkadi L; Bedouelle H
    J Mol Recognit; 2014 Apr; 27(4):205-14. PubMed ID: 24591178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
    Nivarthi UK; Kose N; Sapparapu G; Widman D; Gallichotte E; Pfaff JM; Doranz BJ; Weiskopf D; Sette A; Durbin AP; Whitehead SS; Baric R; Crowe JE; de Silva AM
    J Virol; 2017 Mar; 91(5):. PubMed ID: 28031369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Effects of Monoclonal Antibody against Dengue Virus NS1 in a STAT1 Knockout Mouse Model of Dengue Infection.
    Wan SW; Chen PW; Chen CY; Lai YC; Chu YT; Hung CY; Lee H; Wu HF; Chuang YC; Lin J; Chang CP; Wang S; Liu CC; Ho TS; Lin CF; Lee CK; Wu-Hsieh BA; Anderson R; Yeh TM; Lin YS
    J Immunol; 2017 Oct; 199(8):2834-2844. PubMed ID: 28904127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus.
    Swanstrom JA; Plante JA; Plante KS; Young EF; McGowan E; Gallichotte EN; Widman DG; Heise MT; de Silva AM; Baric RS
    mBio; 2016 Jul; 7(4):. PubMed ID: 27435464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.